Effects of short-term reserpine treatment on generalized and focal dystonic-dyskinetic syndromes.

We report that low dose reserpine treatment (0.25 mg/day for 7 days) improves the dystonic-dyskinetic disability score in patients affected by idiopathic dystonias, iatrogenic dystonic-dyskinetic syndromes and Sydenham's chorea. The results support the idea that the particular antidopaminergic activity exerted by reserpine or other dopamine-depleting agents may produce good therapeutical efficacy, although reserpine can precipitate Parkinsonism and induce dopamine-receptor supersensitivity.